5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
S Vodenkova, T Buchler, K Cervena… - Pharmacology & …, 2020 - Elsevier
Fluorouracil (5-FU) is an essential component of systemic chemotherapy for colorectal
cancer (CRC) in the palliative and adjuvant settings. Over the past four decades, several …
cancer (CRC) in the palliative and adjuvant settings. Over the past four decades, several …
Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence
SR Lin, CH Chang, CF Hsu, MJ Tsai… - British journal of …, 2020 - Wiley Online Library
Traditional chemotherapy is being considered due to hindrances caused by systemic
toxicity. Currently, the administration of multiple chemotherapeutic drugs with different …
toxicity. Currently, the administration of multiple chemotherapeutic drugs with different …
Anti‐inflammatory and anticancer activities of Naringenin‐loaded liquid crystalline nanoparticles in vitro
In this study, we had developed Naringenin‐loaded liquid crystalline nanoparticles (LCNs)
and investigated the anti‐inflammatory and anticancer activities of Naringenin‐LCNs against …
and investigated the anti‐inflammatory and anticancer activities of Naringenin‐LCNs against …
[HTML][HTML] Phenotypic plasticity: driver of cancer initiation, progression, and therapy resistance
PB Gupta, I Pastushenko, A Skibinski, C Blanpain… - Cell stem cell, 2019 - cell.com
Our traditional understanding of phenotypic plasticity in adult somatic cells comprises
dedifferentiation and transdifferentiation in the context of tissue regeneration or wound …
dedifferentiation and transdifferentiation in the context of tissue regeneration or wound …
Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy
Z Yu, H Tang, S Chen, Y Xie, L Shi, S Xia… - Drug Resistance …, 2023 - Elsevier
Aims This study aims at investigating the role of a neighbor long non-coding RNA (lncRNA)
of HDAC4 (LOC85009) in docetaxel (DTX) resistance of lung adenocarcinoma (LUAD) …
of HDAC4 (LOC85009) in docetaxel (DTX) resistance of lung adenocarcinoma (LUAD) …
Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy
Mitotic errors lead to aneuploidy, a condition of karyotype imbalance, frequently found in
cancer cells. Alterations in chromosome copy number induce a wide variety of cellular …
cancer cells. Alterations in chromosome copy number induce a wide variety of cellular …
[HTML][HTML] Dihydroartemisinin: a potential natural anticancer drug
X Dai, X Zhang, W Chen, Y Chen, Q Zhang… - … journal of biological …, 2021 - ncbi.nlm.nih.gov
Dihydroartemisinin (DHA) is an active metabolite of artemisinin and its derivatives (ARTs),
and it is an effective clinical drug widely used to treat malaria. Recently, the anticancer …
and it is an effective clinical drug widely used to treat malaria. Recently, the anticancer …
The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer
DA Senthebane, A Rowe, NE Thomford… - International journal of …, 2017 - mdpi.com
Chemoresistance is a leading cause of morbidity and mortality in cancer and it continues to
be a challenge in cancer treatment. Chemoresistance is influenced by genetic and …
be a challenge in cancer treatment. Chemoresistance is influenced by genetic and …
Nivolumab in combination with platinum‐based doublet chemotherapy for first-line treatment of advanced non–small-cell lung cancer
NA Rizvi, MD Hellmann, JR Brahmer… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Nivolumab, a fully human immunoglobulin G4 programmed death-1 immune
checkpoint inhibitor antibody, has demonstrated improved survival in previously treated …
checkpoint inhibitor antibody, has demonstrated improved survival in previously treated …
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
DA Fennell, Y Summers, J Cadranel, T Benepal… - Cancer treatment …, 2016 - Elsevier
The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the
cisplatin-based doublet remains the foundation of treatment for the majority of patients with …
cisplatin-based doublet remains the foundation of treatment for the majority of patients with …